404 related articles for article (PubMed ID: 33027952)
1. Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II.
Molinaro C; Martoriati A; Pelinski L; Cailliau K
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33027952
[TBL] [Abstract][Full Text] [Related]
2. Gossypol interferes with both type I and type II topoisomerase activities without generating strand breaks.
Senarisoy M; Canturk P; Zencir S; Baran Y; Topcu Z
Cell Biochem Biophys; 2013 May; 66(1):199-204. PubMed ID: 23161103
[TBL] [Abstract][Full Text] [Related]
3. DNA topoisomerases as additional targets for anticancer monofunctional platinum(ii) complexes.
Zhang H; Yang T; Wang Y; Wang Z; Zhu Z; Guo Z; Wang X
Dalton Trans; 2021 Jan; 50(1):304-310. PubMed ID: 33300919
[TBL] [Abstract][Full Text] [Related]
4. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα.
Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE
Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206
[TBL] [Abstract][Full Text] [Related]
5. Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Park S; Thapa Magar TB; Kadayat TM; Lee HJ; Bist G; Shrestha A; Lee ES; Kwon Y
Eur J Med Chem; 2017 Feb; 127():318-333. PubMed ID: 28068603
[TBL] [Abstract][Full Text] [Related]
6. DNA-topoisomerase inhibitors.
D'Incalci M
Curr Opin Oncol; 1993 Nov; 5(6):1023-8. PubMed ID: 8305535
[TBL] [Abstract][Full Text] [Related]
7. Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives.
Nabiev I; Chourpa I; Riou JF; Nguyen CH; Lavelle F; Manfait M
Biochemistry; 1994 Aug; 33(30):9013-23. PubMed ID: 8043587
[TBL] [Abstract][Full Text] [Related]
8. The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.
Yalowich JC; Wu X; Zhang R; Kanagasabai R; Hornbaker M; Hasinoff BB
Biochem Pharmacol; 2012 Jul; 84(1):52-8. PubMed ID: 22503743
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase-targeting chemotherapeutics: what's new?
Cuya SM; Bjornsti MA; van Waardenburg RCAM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):1-14. PubMed ID: 28528358
[TBL] [Abstract][Full Text] [Related]
10. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
11. Clarifying the Mechanism of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα and IIβ.
Keck JM; Conner JD; Wilson JT; Jiang X; Lisic EC; Deweese JE
Chem Res Toxicol; 2019 Oct; 32(10):2135-2143. PubMed ID: 31512855
[TBL] [Abstract][Full Text] [Related]
12. Chiral ruthenium(II) anthraquinone complexes as dual inhibitors of topoisomerases I and II.
Kou JF; Qian C; Wang JQ; Chen X; Wang LL; Chao H; Ji LN
J Biol Inorg Chem; 2012 Jan; 17(1):81-96. PubMed ID: 21858685
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities.
Umemura K; Mizushima T; Katayama H; Kiryu Y; Yamori T; Andoh T
Mol Pharmacol; 2002 Oct; 62(4):873-80. PubMed ID: 12237334
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases?
Bax BD; Sutormin D; McDonald NQ; Burley GA; Shelkovnikova T
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232843
[TBL] [Abstract][Full Text] [Related]
15. DNA repair functions that control sensitivity to topoisomerase-targeting drugs.
Malik M; Nitiss JL
Eukaryot Cell; 2004 Feb; 3(1):82-90. PubMed ID: 14871939
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
Nitiss JL; Wang JC
Mol Pharmacol; 1996 Nov; 50(5):1095-102. PubMed ID: 8913340
[TBL] [Abstract][Full Text] [Related]
17. Efficient hydrolytic cleavage of DNA and antiproliferative effect on human cancer cells by two dinuclear Cu(II) complexes containing a carbohydrazone ligand and 1,10-phenanthroline as a coligand.
Parsekar SU; Singh M; Mishra DP; Antharjanam PKS; Koley AP; Kumar M
J Biol Inorg Chem; 2019 May; 24(3):343-363. PubMed ID: 30887122
[TBL] [Abstract][Full Text] [Related]
18. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
[TBL] [Abstract][Full Text] [Related]
19. Selective anticancer copper(II)-mixed ligand complexes: targeting of ROS and proteasomes.
Ng CH; Kong SM; Tiong YL; Maah MJ; Sukram N; Ahmad M; Khoo AS
Metallomics; 2014 Apr; 6(4):892-906. PubMed ID: 24549332
[TBL] [Abstract][Full Text] [Related]
20. Structure elucidation {spectroscopic, single crystal X-ray diffraction and computational DFT studies} of new tailored benzenesulfonamide derived Schiff base copper(II) intercalating complexes: Comprehensive biological profile {DNA binding, pBR322 DNA cleavage, Topo I inhibition and cytotoxic activity}.
Afsan Z; Roisnel T; Tabassum S; Arjmand F
Bioorg Chem; 2020 Jan; 94():103427. PubMed ID: 31735357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
